Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker LXEO
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Louis Edward Tamayo Chief Financial Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 4,117 | $4.91 | $20.2K Sale | Form 4 ↗ |
| Aug 18, 2026 | Jose Manuel Otero Chief Operating Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 1,304 | $4.96 | $6,468 Sale | Form 4 ↗ |
| Aug 18, 2026 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 3,345 | $4.95 | $16.6K Sale | Form 4 ↗ |
| Jul 1, 2026 | Narinder Pal Bhalla Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 22,306 | $4.42 | $98.6K Sale | Form 4 ↗ |
| Jul 1, 2026 | Louis Edward Tamayo Chief Financial Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 4,641 | $4.49 | $20.8K Sale | Form 4 ↗ |
| Jul 1, 2026 | Jose Manuel Otero Chief Operating Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 4,666 | $4.48 | $20.9K Sale | Form 4 ↗ |
| Jul 1, 2026 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 25,947 | $4.48 | $116.2K Sale | Form 4 ↗ |
| May 18, 2026 | Jose Manuel Otero Chief Operating Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 1,302 | $5.07 | $6,601 Sale | Form 4 ↗ |
| May 18, 2026 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 3,342 | $5.06 | $16.9K Sale | Form 4 ↗ |
| Apr 6, 2026 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 55,000 | $5.69 | $312.9K Sale | Form 4 ↗ |
| Feb 18, 2026 | Jose Manuel Otero Chief Operating Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 3,016 | $6.40 | $19.3K Sale | Form 4 ↗ |
| Feb 18, 2026 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 10,173 | $6.38 | $64.9K Sale | Form 4 ↗ |
| Nov 18, 2025 | Jose Manuel Otero Chief Operating Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 721 | $9.27 | $6,684 Sale | Form 4/A ↗ |
| Nov 18, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 386 | $9.27 | $3,578 Sale | Form 4 ↗ |
| Nov 18, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 1,127 | $9.27 | $10.4K Sale | Form 4 ↗ |
| Nov 18, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 549 | $9.27 | $5,089 Sale | Form 4 ↗ |
| Nov 18, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 615 | $9.27 | $5,701 Sale | Form 4 ↗ |
| Oct 17, 2025 | Jose Manuel Otero Chief Technical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 24 | $9.56 | $229 Sale | Form 4 ↗ |
| Oct 17, 2025 | Jose Manuel Otero Chief Technical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 2,091 | $8.94 | $18.7K Sale | Form 4 ↗ |
| Oct 17, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 44 | $9.56 | $421 Sale | Form 4 ↗ |
| Oct 17, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 3,844 | $8.94 | $34.4K Sale | Form 4 ↗ |
| Oct 17, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 148 | $9.56 | $1,415 Sale | Form 4 ↗ |
| Oct 17, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 12,985 | $8.94 | $116.1K Sale | Form 4 ↗ |
| Oct 17, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 40 | $9.56 | $382 Sale | Form 4 ↗ |
| Oct 17, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 3,486 | $8.94 | $31.2K Sale | Form 4 ↗ |
| Oct 17, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 38 | $9.56 | $363 Sale | Form 4 ↗ |
| Oct 17, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 3,344 | $8.94 | $29.9K Sale | Form 4 ↗ |
| Aug 18, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 1,115 | $4.67 | $5,207 Sale | Form 4/A ↗ |
| Aug 18, 2025 | Jose Manuel Otero Chief Technical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 2,848 | $4.67 | $13.3K Sale | Form 4 ↗ |
| Aug 18, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 542 | $4.67 | $2,531 Sale | Form 4 ↗ |
| Aug 18, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 608 | $4.67 | $2,839 Sale | Form 4 ↗ |
| Aug 18, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 382 | $4.67 | $1,784 Sale | Form 4 ↗ |
| May 16, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 1,074 | $2.77 | $2,975 Sale | Form 4 ↗ |
| May 16, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 585 | $2.77 | $1,620 Sale | Form 4 ↗ |
| May 16, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 521 | $2.77 | $1,443 Sale | Form 4 ↗ |
| May 16, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 367 | $2.77 | $1,017 Sale | Form 4 ↗ |
| Feb 19, 2025 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 4,326 | $4.41 | $19.1K Sale | Form 4 ↗ |
| Feb 19, 2025 | Tai Sandi See Chief Development Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 1,486 | $4.41 | $6,553 Sale | Form 4 ↗ |
| Feb 19, 2025 | Eric Adler Chief Medical Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 2,359 | $4.41 | $10.4K Sale | Form 4 ↗ |
| Feb 19, 2025 | Jenny Robertson Chief Legal Officer | LXEO Lexeo Therapeutics, Inc. | Sale | 2,101 | $4.41 | $9,265 Sale | Form 4 ↗ |
| Dec 10, 2024 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 2,500 | $8.20 | $20.5K Sale | Form 4 ↗ |
| Nov 25, 2024 | Paula H. Cholmondeley Director | LXEO Lexeo Therapeutics, Inc. | Buy | 15,000 | $6.99 | $104.8K Buy | Form 4 ↗ |
| Nov 11, 2024 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 2,500 | $7.82 | $19.6K Sale | Form 4 ↗ |
| Oct 10, 2024 | Richard Nolan Townsend Chief Executive Officer, Director | LXEO Lexeo Therapeutics, Inc. | Sale | 5,000 | $8.10 | $40.5K Sale | Form 4 ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:11 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances